- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
Outcomes With Salvage Therapies in RRMM Post-CAR T Relapse Indicate an Area of Unmet Need
August 27, 2022
Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.
Roundtable Discussion: Barriers to CAR T-Cell Therapy for DLBCL Lead to Debate About Targeted Therapy
August 27, 2022
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
Challenges With CAR T Therapy in Community Practices
August 23, 2022
Peter A. McSweeney, MD, discusses challenges with implementing chimeric antigen receptorT-cell therapy in some community oncology practices.
Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study
August 19, 2022
Treatment with CD30 chimeric antigen receptor T-cell therapy combined with a monoclonal antibody has begun in the phase 1b ACTION study of patients with relapsed or refractory classical Hodgkin lymphoma.
Anakinra Manages ICANS/CRS Toxicity Induced by CAR T-Cell Therapy
August 14, 2022
Nicolas Gazeau discusses a retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who have received chimeric antigen receptor T-cell therapy.
CAR T-Cell Treatment at Higher Doses Reveal Beneficial Survival Data Without Worry of Added Toxicity
August 12, 2022
Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables.
Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell Lymphoma
August 10, 2022
Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.
FDA Lifts Clinical Hold on KEYNOTE-B79 Trial of a Novel CAR T-Cell Agent in mCRC
August 01, 2022
The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer.
Manipulating T Cells to Treat Patients With Cancer
July 24, 2022
Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Survey Identifies Obstacles to Adoption of CAR T-Cell Therapy for DLBCL
July 13, 2022
Bruce Feinberg, DO, discusses a survey researching chimeric antigen receptor T-cell therapy’s growing usage by community oncologists for diffuse large B-cell lymphoma.